Deciphera Pharmaceuticals Inc. started an offering to sell 3,750,000 common shares.
The company also plans to grant the underwriters an option to buy up to 562,500 shares.
J.P. Morgan and Piper Jaffray are acting as joint book-running managers for the offering.
Waltham, Mass.-based Deciphera Pharmaceuticals is a biotechnology company that develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread.
